Paris (France), January 8. 2024. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, today announced the outcome of its regulatory interactions with the US Food and Drug Administration (FDA) to finalize the design of a single Phase 3 registration trial (ACCURATE) for nangibotide in septic shock. The
L’article Inotrem successfully reaches agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock est apparu en premier sur Inotrem.